Champignon Brands is proposing changing its corporate name to Apotheosis Scientific Ltd, and announces a planned spin-off its consumer packaged goods (CPG) division.
Psychedelics
Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation
Mydecine announces research agreement with a leading pharmacology research institution.
Mydecine Innovations Inks Important Research Agreement
Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
Mira X Acquisition Corp. Announces Proposed Qualifying Transaction with Field Trip Psychedelics Inc
Field Trip Psychedelics is planning to go public via a "three-cornered" RTO.
What Does Field Trip Psychedelics Offer Investors?
Field Trip Psychedelics has just announced a letter of intent to go public via RTO.
New Wave Holdings Appoints Dr. Dennis McKenna to Psychedelic Research Advisory Board
New Wave Holdings Corp has added a recognized expert in psychedelic medicine to the company's Advisory Board.
GreenStar Biosciences Signs Agreement to Acquire 100% of Eleusian Biosciences Corp.
Greenstar Biosciences is entering the psychedelics space via its acquisition of Eleusian Biosciences Corp.
Red Light Holland Announces The Closing of Second Tranche of Private Placement
With the closing of its second tranche, Red Light Holland has now raised $3,830,529 in its current private placement.
Mydecine Innovations Signs Definitive Agreement to Acquire Mindleap Health's Advanced Digital Telehealth Platform
Mydecine is acquiring the Digital Telehealth Platform of Mindleap Health Inc in a cash and shares deal.
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In A Phase 1 Clinical Trial Collaboration
MindMed is adding to its clinical trials on psychedelics with a Phase 1 collaboration aimed at ayahuasca research.
Champignon Brands Announces Regulatory Review, Cease Trade Order
Trading of Champignon Brands (SHRM) on the Canadian Securities Exchange has been temporarily halted due to the failure to file necessary disclosures with respect to recent acquisitions.
MindMed And Eleusis Lead The Way In Psychedelics Micro-Dosing Research
Given that psychedelics micro-dosing has several commercial advantages, here are two companies that investors should look at.
Mydecine Innovations Group Adds a Leading Neuroscientist and a Psychopharmacology Specialist
Mydecine's new Scientific Advisor will work directly with the CSO in new drug development initiatives.
COMPASS Pathways Strengthens Leadership Team With Appointment of Trevor Mill as Chief Development Officer
Compass appoints a new Chief Development Officer as part of several new appointments to its management team.
Canadians More Receptive To Use Of Psilocybin For The Terminally Ill: New Poll
Canadians are rapidly warming up to the idea of using psilocybin to reduce distress among the terminally ill.